STORM Therapeutics
- Health & Biotech
- Cambridge, GB
- Private
- stormtherapeutics.com
Cambridge (UK) cancer drug developer whose lead candidate STC-15, a METTL3 inhibitor, is in a Phase 2 sarcoma trial.
$56MEquity raised in 2025–20262025 — · 2026 $56M · 1 equity round
$56MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 3 sources
Earlier rounds not yet sourced. STORM Therapeutics raised before 16 Apr 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series CAmount$56MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 6
- Fast Track Initiative (FTI)
- IP Group plc
- M Ventures
- Pfizer Ventures
- Taiho Ventures
- UTokyo Innovation Platform Co., Ltd.
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
Also in the Cambridge hub see on the globe
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. STORM Therapeutics and its logo are trademarks of their owners, used here for identification only.
